18 June 2013
Keywords: pozen/gsk, trexima, target, nda, firm, pozen, says
Article | 27 April 2005
US firm POZEN says that all primary endpoints of its second Phase III clinical trial of migraine drug Trexima (sumatriptan ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 April 2005
26 April 2005
28 April 2005
© 2013 thepharmaletter.com